Actively Recruiting
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
Led by Emory University · Updated on 2025-10-08
100
Participants Needed
1
Research Sites
72 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
D
DexCom, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to compare inpatient glycemic control by measuring the percentage of time in the range of 70-180 mg/dl and the frequency of hypoglycemia between Dexcom G7 Continuous Glucose Monitoring (CGM) and Point of Care (POC) Blood Glucose Testing in poorly controlled subjects with Type 1 Diabetes Mellitus. The main question it aims to answer is: -Whether there is a difference between POC testing (standard of care) and Real-time CGM in glycemic control and hypoglycemic events during hospitalization:
CONDITIONS
Official Title
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Known history of Type 1 Diabetes treated with insulin therapy including rapid-acting, intermediate-acting, or long-acting formulations
- Admission diagnosis of poorly controlled Type 1 Diabetes with blood glucose over 180 mg/dl or HbA1c over 7%, including diabetic ketoacidosis or hyperglycemic hyperosmolar state
- Expected hospital stay longer than three days at the time of randomization
You will not qualify if you...
- Admission to an intensive care unit
- Use of continuous glucose monitoring technology before admission
- Diagnosis of type 2 diabetes
- Treatment with systemic immunosuppressive agents
- Diagnosis of cystic fibrosis
- Prisoner status
- Expected need for MRI procedures during hospitalization
- Pregnancy or breastfeeding at enrollment
- Unwillingness to wear a continuous glucose monitoring device
- Clinically relevant liver disease or end-stage kidney disease, or terminal illness
- History of cognitive impairment, dementia, or mental conditions impairing understanding of the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Actively Recruiting
Research Team
G
Guillermo Umpierrez, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here